ArticleLipids in health and disease2026
Gender differences in the plasma profiles of proprotein convertase subtilisin/kexin-type 9 (PCSK9), soluble low-density lipoprotein receptor (sLDLR), total cholesterol, and triglycerides in patients with colorectal cancer liver metastases: diagnostic and prognostic implications.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProprotein convertase subtilisin/kexin-type 9 (PCSK9) and soluble low-density lipoprotein receptor (sLDLR) are circulating proteins that down regulate LDLR-mediated uptake of plasma LDL-cholesterol into cells. In healthy individuals, plasma PCSK9 and sLDLR levels correlate with total cholesterol and triglycerides, respectively. Because cancer reprograms lipid metabolism, it may alter both the circulating levels of these proteins and their correlations with total cholesterol and triglycerides. To test this possibility, we measured PCSK9, sLDLR, total cholesterol, and triglycerides in plasma from healthy subjects and patients with colorectal cancer liver metastases (CRLM), classified as early recurrent or non-recurrent after liver resection.
methodsPlasma PCSK9 and sLDLR were measured using specific ELISA kits. Total cholesterol and triglycerides were measured by enzymatic colorimetry.
resultsCompared with healthy subjects, CRLM patients had 4- to 6-fold higher sLDLR levels, regardless of recurrence category or gender (P < 0.0001). sLDLR strongly correlated with triglyceride levels (P < 0.0001). Correlations between PCSK9 and sLDLR, total cholesterol, and triglycerides varied by gender and CRLM category. Low PCSK9 levels were associated with larger tumors in early recurrent CRLM, particularly in women (P < 0.01). In women, total cholesterol above the median predicted poorer 5-year overall survival [HR (95% CI), 1.70 (1.07-2.71); P = 0.0152].
conclusionsElevated plasma sLDLR is a candidate diagnostic biomarker for CRLM. In women with early recurrent CRLM, low plasma PCSK9 may indicate large tumors, whereas elevated plasma total cholesterol is an adverse prognostic biomarker. These findings identify early recurrence and gender as important variables when interpreting the clinical significance of lipid dysregulation in CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.